Biological products, (no disgnostic substances) Sample Contracts

Taysha Gene Therapies, Inc.LEASE (March 3rd, 2021)

This LEASE (this “Lease”) is executed this 17th day of December, 2020, by and between PATRIOT PARK PARTNERS II, LLC, a Delaware limited liability company (“Landlord”), and TAYSHA GENE THERAPIES, INC., a Delaware corporation (“Tenant”).

Passage BIO, Inc.AMENDED AND RESTATED EMPLOYMENT AGREEMENT (March 3rd, 2021)

THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into effective as of November 12, 2018 by and between Passage BIO, Inc. (the “Company”), and Jill Quigley (“Ms. Quigley”) (collectively, the “Parties”). This Agreement amends, restates and supersedes any prior written employment agreement between the Parties and any other written or unwritten agreement or understanding between the Parties regarding the subject matter hereof.

Taysha Gene Therapies, Inc.LICENSE AGREEMENT (March 3rd, 2021)

This License Agreement (this “Agreement”) is dated as of October 29, 2020 (the “Effective Date”) by and between Abeona Therapeutics Inc., a Delaware corporation having its principal place of business at 1330 Avenue of the Americas, Suite 33A, New York, NY 10019 (“Licensor”), and Taysha Gene Therapies, Inc., a Delaware corporation having a place of business at 2280 Inwood Road, Dallas, TX 75325 (“Company”). Licensor and Company may be referred to herein as a “Party” or, collectively, as “Parties”.

Axcella Health Inc.EMPLOYMENT AGREEMENT (March 3rd, 2021)

This Employment Agreement (“Agreement”) is made as of the 2nd Day of March, 2021 between Axcella Health Inc., a Delaware corporation (the “Company”), and Alison Schecter (the “Executive”).

Fusion Pharmaceuticals Inc.ASSET PURCHASE AGREEMENT dated as of March 1, 2021 by and between IPSEN PHARMA SAS and FUSION PHARMACEUTICALS INC. (March 2nd, 2021)

This Asset Purchase Agreement (this “Agreement”), dated as of March 1, 2021, is entered into by and between Fusion Pharmaceuticals Inc., a Canadian federal corporation (“Buyer”), and Ipsen Pharma SAS, a French société par actions simplifiée (“Seller”). Seller and Buyer are sometimes referred to in this Agreement collectively as the “Parties” and individually as a “Party”.

Mosaic ImmunoEngineering Inc.FORM OF INDEMNIFICATION AGREEMENT (March 2nd, 2021)

This Indemnification Agreement (“Agreement”) is made as of [_______], by and between Mosaic ImmunoEngineering Inc., a Delaware corporation (the “Company”), and [________], (“Indemnitee”).

Redmile Group, LLCJoint Filing Agreement (March 2nd, 2021)

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.01 par value per share, of Ayala Pharmaceuticals, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.

Revolution Medicines, Inc.REVOLUTION MEDICINES, INC. INDENTURE Dated as of ___________, 20__ as Trustee (March 2nd, 2021)

Indenture dated as of __________, 20__ between Revolution Medicines, Inc., a company incorporated under the laws of Delaware (“Company”), and [ ] (“Trustee”).

Bluebird Bio, Inc.Amendment No. 3 to Clinical and Commercial Supply Agreement Viral Vector Product (February 23rd, 2021)

This Amendment No. 3 to the Clinical and Commercial Supply Agreement-Viral Vector Product (the “Amendment”) is made effective January 1, 2021, (“Amendment Effective Date”) by and between bluebird bio (Switzerland) GmbH (“Company”), and SAFC Carlsbad, Inc., a California corporation (“SAFC”). Company and SAFC may hereinafter be referred to as a Party or as the Parties. Capitalized terms used but not otherwise defined herein shall have the meanings given to such terms in the Agreement.

Halozyme Therapeutics, Inc.Halozyme Therapeutics, Inc. Performance Stock Units Agreement under the Halozyme Therapeutics, Inc. (February 23rd, 2021)
Genocea Biosciences, Inc.Portions of this exhibit have been redacted because they are both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark ... (February 22nd, 2021)

THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of February 18, 2021 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (together with any successor or assignee “Bank”), and GENOCEA BIOSCIENCES, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows:

Xtant Medical Holdings, Inc.REGISTRATION RIGHTS AGREEMENT (February 22nd, 2021)

This Registration Rights Agreement (this “Agreement”) is made and entered into as of February __, 2021, by and between Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser”and, collectively, the “Purchasers”).

Xtant Medical Holdings, Inc.Xtant Medical Holdings, Inc. (February 22nd, 2021)
Compugen LTDAmendment No. 2 to Master Clinical Trial Collaboration Agreement (February 22nd, 2021)

This Amendment No. 2 to Master Clinical Trial Collaboration Agreement (this “Amendment”) is effective as of February 19, 2021 (“Amendment Effective Date”) by and between Compugen Ltd., an Israeli corporation with a place of business at Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849, Israel (“Compugen”), and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 430 E. 29th Street, 14FL, New York, N.Y. 10016 (“BMS”).

Cannabis Global, Inc.STOCK PURCHASE AGREEMENT (February 22nd, 2021)

This Stock Purchase Agreement (this “Agreement”), dated as of February 16, 2021, is entered into between Alan Tsai, an individual (“Tsai”), and Cannabis Global, Inc., a Nevada corporation (“CGI”). Capitalized terms used in this Agreement have the meanings given to such terms herein.

Ayala Pharmaceuticals, Inc.SECURITIES PURCHASE AGREEMENT (February 22nd, 2021)

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of February 19, 2021 by and among Ayala Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively, the “Investors”).

Citadel Advisors LLCJOINT FILING AGREEMENT (February 22nd, 2021)

This Agreement may be executed in counterparts and each of such counterparts taken together shall constitute one and the same instrument.

Genocea Biosciences, Inc.Contract (February 22nd, 2021)

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

Genocea Biosciences, Inc.SUBLEASE (February 22nd, 2021)

This instrument is a Sublease (the “Sublease”) dated as of November 30, 2020 (the “Execution Date”) between GENOCEA BIOSCIENCES, INC., a Delaware corporation (“Sublessor”), and ZYMERGEN INC., a Delaware corporation (“Sublessee”). The parties to this instrument hereby agree with each other as follows:

Xtant Medical Holdings, Inc.SECURITIES PURCHASE AGREEMENT (February 22nd, 2021)

This Securities Purchase Agreement (this “Agreement”) is dated as of February 22, 2021, between Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

Cannabis Global, Inc.SHAREHOLDERS AGREEMENT among NATURAL PLANT EXTRACT OF CALIFORNIA, INC. and EACH PERSON IDENTIFIED ON SCHEDULE A (February 22nd, 2021)

This Shareholders Agreement (this “Agreement”), dated as of June 5, 2020 (the “Effective Date”), is entered into among Natural Plant Extract of California, Inc., a California Company (the “Company”), each Person identified on Schedule A hereto as a Major Shareholder (each, a “Major Shareholder” and collectively, the “Major Shareholders”), each Person identified on Schedule A hereto as a Shareholder, and each other Person who after the date hereof acquires Shares of the Company and becomes a party to this Agreement by executing a Joinder Agreement (such Persons, collectively with the Major Shareholders, the “Shareholders”).

Sorrento Therapeutics, Inc.LICENSE AGREEMENT (February 19th, 2021)

This License Agreement (this “Agreement”) is made as of October 12, 2020 (the “Agreement Date”), by and between Sorrento Therapeutics, Inc., a Delaware corporation (“Sorrento”) and Personalized Stem Cells, Inc., a Delaware corporation (“PSC”). Sorrento and PSC shall be referred to herein individually as a “Party” and collectively as the “Parties.”

Creative Medical Technology Holdings, Inc.SECURITIES PURCHASE AGREEMENT (February 18th, 2021)

This Securities Purchase Agreement (this “Agreement”) is dated as of February 11, 2021, between Creative Medical Technology Holdings, Inc., a Nevada corporation (the “Company”), and BHP Capital NY, Inc. (the “Purchaser”).

Aspire Capital Fund, LLCJOINT FILING AGREEMENT (February 17th, 2021)

This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.

Seagen Inc.Contract (February 12th, 2021)
Seagen Inc.CONFIDENTIAL -vi- [*] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed. INDEX OF DEFINED TERMS Adverse Event ... (February 12th, 2021)
Novartis Pharma AgJoint Filing Agreement (February 12th, 2021)

This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.

Kiser 2012 Gift TrustAGREEMENT REGARDING THE JOINT FILING OF AMENDMENT NO. 3 TO SCHEDULE 13G (February 12th, 2021)
Syncona Portfolio LTDAGREEMENT (February 12th, 2021)

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Ordinary Shares (represented by ADS, each of which represents one Ordinary Share) of Freeline Therapeutics Holdings plc and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. It is understood and agreed that the joint filing of the Schedule 13G shall not be construed as an admission that the persons named herein constitute a group for purposes of Regulation 13D-G of the Securities Exchange Act of 1934, as amended.

Castellina Ventures Ltd.Joint Filing Agreement (February 12th, 2021)

In accordance with Rule 13d-1(k) under the Securities and Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule 13G. In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement as of February 12, 2021.

Allovir, Inc.FIRST AMENDMENT TO THE AMENDED & RESTATED EXCLUSIVE LICENSE AGREEMENT (February 12th, 2021)

This First Amendment to the Amended and Restated Exclusive License Agreement (hereinafter called “First Amendment”), to be effective as of the 30th day of November 2020 (hereinafter called “Amendment Date”), is by and between Baylor College of Medicine (hereinafter called “BCM”), a Texas nonprofit corporation having its principal place of business at One Baylor Plaza, Houston, Texas 77030, and ALLOVIR, INC., a corporation organized under the laws of Delaware and having a principal place of business at 2925 Richmond Ave., Suite 1274, Houston, Texas, 77098 and its Affiliates (hereinafter, collectively referred to as "LICENSEE"). The Amended and Restated Exclusive License Agreement, dated May 11, 2020, is referred to herein as the “Viral Infection License Agreement.” BCM and LICENSEE are sometimes referred to herein individually as a “Party” and are sometimes referred to herein collectively as the “Parties”.

Allovir, Inc.EXCLUSIVE LICENSE AGREEMENT (February 12th, 2021)

This Exclusive License Agreement (hereinafter called “Agreement”), to be effective as of the 30th day of November 2020 (hereinafter called “Agreement Date”), is by and between Baylor College of Medicine (hereinafter called “BCM”), a Texas nonprofit corporation having its principal place of business at One Baylor Plaza, Houston, Texas 77030, and ALLOVIR, INC., a corporation organized under the laws of Delaware and having a principal place of business at 2925 Richmond Ave., Suite 1274, Houston, Texas, 77098 and its Affiliates (hereinafter, collectively referred to as "LICENSEE"). BCM and LICENSEE are sometimes referred to herein individually as a “Party” and are sometimes referred to herein collectively as the “Parties”.

Seagen Inc.* ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED Amendment and without any further action ... (February 12th, 2021)
Bpifrance Participations SAJOINT FILING AGREEMENT (February 12th, 2021)

This Agreement may be executed in counterparts and each of such counterparts taken together shall constitute one and the same instrument.

Omega Fund VI, L.P.AGREEMENT (February 12th, 2021)

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Checkmate Pharmaceuticals, Inc.